US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

A research group at LMU University Hospital has investigated how Alzheimer's disease can be diagnosed more reliably in the ...

Moreover, CSF analysis provides indirect, non-quantitative evidence of amyloid deposits in the brain. Method number 2 involves a technique for imaging the brain called positron emission tomography ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...

The members of the Amyloid imaging to prevent Alzheimer's disease (AMYPAD) have announced the publication of a perspective ...

When I co-invented the first PET (positron emission tomography) scan to visualize brain amyloid and tau—the physical evidence of Alzheimer’s disease—I did not foresee the distressing mental ...